Nucleophosmin (NPM1) Mutation Analysis
NY State Approved Indicates the status of NY State approval and if the test is orderable for NY State clients.
As a prognostic indicator in patients with newly diagnosed acute myelogenous leukemia with normal karyotype and no FLT3 mutation
Testing Algorithm Delineates situation(s) when tests are added to the initial order. This includes reflex and additional tests.
Special Instructions and Forms Describes specimen collection and preparation information, test algorithms, and other information pertinent to test. Also includes pertinent information and consent forms to be used when requesting a particular test
DNA Polymerase Chain Reaction (PCR) with Fragment Analysis by Capillary Gel Electrophoresis
(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
Reporting Name A shorter/abbreviated version of the Published Name for a test; an abbreviated test name
Nucleophosmin Mutation Analysis